<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04464421</url>
  </required_header>
  <id_info>
    <org_study_id>20-07418-XP UM</org_study_id>
    <nct_id>NCT04464421</nct_id>
  </id_info>
  <brief_title>SMART Trial Efficacy Study</brief_title>
  <official_title>Pilot Test of Contingency Management and Brief Motivational Interviewing + Substance Free Activity Session Interventions + Mindfulness-Based Adherence Promotion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karen Derefinko, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Memphis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Tennessee</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of two different interventions for
      medication-assisted treatment (MAT) adherence: Contingency Management (CM) and Brief
      Motivational Intervention plus Substance Free Activities Session plus Mindfulness-Based
      Adherence Promotion (BMI+SFAS+MBAP). If the interventions are efficacious, they will be used
      in a larger trial with a SMART (Sequential Multiple Assignment Randomized Trial) design.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 20, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Buprenorphine adherence</measure>
    <time_frame>through study completion, an average of 4 months</time_frame>
    <description>Positive buprenorphine in urine toxicology screen at each visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Attendance at physician visits</measure>
    <time_frame>through study completion, an average of 4 months</time_frame>
    <description>Treatment adherence measured by whether or not patient completes their first four scheduled follow-ups with their physician based on the clinic's standard of care schedule.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Opioid-use Disorder</condition>
  <condition>Opioid Dependence</condition>
  <condition>Treatment Adherence</condition>
  <arm_group>
    <arm_group_label>Contingency management (CM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive physical rewards urine toxicology results are positive for buprenorphine (i.e., they are adherent to Medication-Assisted Treatment (MAT)) during their first four visits after initiation of MAT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BSM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BSM (Brief Motivational Intervention + Substance Free Activities Session + Mindfulness-Based Adherence Promotion) participants will have one-on-one behavioral intervention sessions at each of the first four visits after initiation of MAT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Contingency Management (CM)</intervention_name>
    <description>Participants will be able to draw a gift card from a fishbowl when their urine toxicology results are positive for buprenorphine (i.e., they are adherent to Medication-Assisted Treatment). Gift cards in the bowl for drawing will be $25, $50, or $100.</description>
    <arm_group_label>Contingency management (CM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Brief Motivational Intervention + Substance Free Activities Session + Mindfulness-Based Adherence Promotion (BSM)</intervention_name>
    <description>Participants will have one-on-one sessions with a behavioral interventionist to discuss their goals regarding treatment, how to reach these goals, and the importance of substance-free activities.</description>
    <arm_group_label>BSM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Present for an intake appointment at study site for treatment of opioid use disorder.

          -  Eligible for receipt of buprenorphine-naloxone treatment (e.g. Suboxone, Bunavil,
             Zubsolv) as determined by clinic physicians

          -  18 years or older

          -  Access to a telephone

          -  Ability to comprehend consent and intervention materials (approximately 8th-grade
             level).

        Exclusion Criteria:

          -  Physician expects that patient will not follow standard treatment visit schedule
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen J Derefinko, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tennessee Health Science Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Hand, MPH, CCRP</last_name>
    <phone>901-448-3072</phone>
    <email>shand@uthsc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dana Guerrero, BS</last_name>
    <phone>901-448-3174</phone>
    <email>dguerre2@uthsc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Tennessee Health Science Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2020</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Tennessee</investigator_affiliation>
    <investigator_full_name>Karen Derefinko, PhD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>opioid use disorder</keyword>
  <keyword>OUD</keyword>
  <keyword>buprenorphine</keyword>
  <keyword>treatment adherence</keyword>
  <keyword>substance-free activities</keyword>
  <keyword>brief motivational interviewing</keyword>
  <keyword>contingency management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

